Marlborough, Mass.-based Boston Scientific said the Reduce-HTN: Reinforce trial will include a 4-week pre-enrollment "washout" period during which patients are weaned from their anti-high blood pressure medications.
The randomized, sham-controlled, multicenter study is slated to enroll 100 patients, the company said. The primary efficacy endpoint is mean reduction in average 24-hour ambulatory blood pressure at 8 weeks. Boston said it could post 1st results as early as the 1st half of next year.
"We believe the Vessix system is a meaningful innovation to help advance the care of patients with hypertension," peripheral interventions president Jeff Mirviss said in prepared remarks. "That is why we worked with the broader hypertension clinical community to develop a unique and comprehensive study that will provide critical data to inform the field and demonstrate the true effect of renal denervation in reducing high blood pressure."
Boston Scientific is the 2nd company this month to re-enter the RDN race, after Medtronic (NYSE:MDT) said it’s taking another crack at it with the launch of study examining the "confounding factors" that contributed to the high-profile failure of a prior trial.
Back in January 2014, Fridley, Minn.-based Medtronic shocked medtech when it announced that the highly anticipated Symplicity-3 trial failed to meet its efficacy endpoint. The company suspend enrollment in its other Symplicity trials around the world and later took a $200 million writedown on its renal denervation assets.
News of the trials failure reverberated throughout the medical device industry, prompting other companies to follow suit by either scaling back their RDN programs or spiking them altogether.
Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.